Cephalon finds Gabitril fails to help generalized anxiety disorder

New York, June 26 - Cephalon, Inc. said its phase 3 clinical trial of Gabitril (tiagabine hydrochloride) for generalized anxiety disorder did not reach statistical significance on the primary study endpoints.

The Frazer, Pa., biopharmaceutical company said it will conduct a complete analysis of the data to assist in its evaluation of future clinical development plans for Gabitril in other therapeutic areas.

Gabitril is currently marketed in the United States and Europe as adjunctive therapy in adults and children 12 years and older in the treatment of partial seizures.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.